My thought on $ADXS

3 มี.ค. 2021

I have been looking for ADXS action lately. Good swings if you have stomach for it.
Near-term target $1.20


Long term
The company has cash into 2022.
A few catalysts

• ADXS-HOT: Off-the-shelf, tumor type-specific constructs
  ADXS-503 in NSCLC in Phase 1/2 study
  ADXS-504 in prostate cancer scheduled to enter the clinic in Q1 2021
  

Forthcoming Milestones

*ADXS-503: Phase 1/2 combination with KEYTRUDA--clinical and immune/biomarker data for KEYTRUDA failures as well as first-line patients
ADXS-504: Clinical trial initiation; initial data readout
ADXS-PSA: Announcement of next steps

The first patient dosed with HOT-Prostate by Q1 2021